Primary esophageal malignant melanoma without recurrence after surgery and adjuvant therapy with nivolumab.

IF 0.5 Q4 ONCOLOGY
International Cancer Conference Journal Pub Date : 2022-12-21 eCollection Date: 2023-04-01 DOI:10.1007/s13691-022-00582-7
Sho Nambara, Yoshihisa Sakaguchi, Yasuo Tsuda, Kensuke Kudou, Eiji Kusumoto, Rintaro Yoshida, Tetsuya Kusumoto, Koji Ikejiri
{"title":"Primary esophageal malignant melanoma without recurrence after surgery and adjuvant therapy with nivolumab.","authors":"Sho Nambara, Yoshihisa Sakaguchi, Yasuo Tsuda, Kensuke Kudou, Eiji Kusumoto, Rintaro Yoshida, Tetsuya Kusumoto, Koji Ikejiri","doi":"10.1007/s13691-022-00582-7","DOIUrl":null,"url":null,"abstract":"<p><p>Primary malignant melanoma of the esophagus is a rare disease with a severely poor prognosis. Here, we report a patient with primary malignant melanoma of the esophagus surviving without recurrence after surgery and adjuvant therapy with nivolumab. The patient was a 60-year-old female with dysphagia. Esophagogastroscopy showed an elevated dark brown tumor in the lower thoracic esophagus. A histological examination of the biopsy revealed human melanoma black 45 and melan-A positivity. The patient was diagnosed with primary malignant melanoma of the esophagus and was treated with radical esophagectomy. As postoperative treatment, the patient was given nivolumab (240 mg/body) every 2 weeks. Although bilateral pneumothorax occurred after 2 courses, she recovered after chest drainage. Nivolumab treatment is still ongoing over 1 year after the surgery, and the patient has survived without recurrence. We conclude that nivolumab is an optimal option as a postoperative adjuvant treatment for PMME.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 2","pages":"100-103"},"PeriodicalIF":0.5000,"publicationDate":"2022-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989119/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Cancer Conference Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13691-022-00582-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/4/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Primary malignant melanoma of the esophagus is a rare disease with a severely poor prognosis. Here, we report a patient with primary malignant melanoma of the esophagus surviving without recurrence after surgery and adjuvant therapy with nivolumab. The patient was a 60-year-old female with dysphagia. Esophagogastroscopy showed an elevated dark brown tumor in the lower thoracic esophagus. A histological examination of the biopsy revealed human melanoma black 45 and melan-A positivity. The patient was diagnosed with primary malignant melanoma of the esophagus and was treated with radical esophagectomy. As postoperative treatment, the patient was given nivolumab (240 mg/body) every 2 weeks. Although bilateral pneumothorax occurred after 2 courses, she recovered after chest drainage. Nivolumab treatment is still ongoing over 1 year after the surgery, and the patient has survived without recurrence. We conclude that nivolumab is an optimal option as a postoperative adjuvant treatment for PMME.

原发性食管恶性黑色素瘤在接受手术和 nivolumab 辅助治疗后无复发。
食管原发性恶性黑色素瘤是一种预后极差的罕见疾病。在此,我们报告了一名食管原发性恶性黑色素瘤患者,该患者在接受手术和尼伐单抗辅助治疗后无复发,并存活了下来。患者是一名 60 岁的女性,伴有吞咽困难。食管胃镜检查显示下胸段食管有一个隆起的黑褐色肿瘤。活检组织学检查显示人类黑色素瘤黑色 45 和黑色素-A 阳性。患者被诊断为食管原发性恶性黑色素瘤,并接受了食管根治术。术后,患者接受了每两周一次的 nivolumab(240 毫克/体)治疗。虽然在两个疗程后出现了双侧气胸,但她在胸腔引流后恢复了健康。术后 1 年多,患者仍在接受尼妥珠单抗治疗,并且没有复发。我们的结论是,作为 PMME 的术后辅助治疗,nivolumab 是一种最佳选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
14.30%
发文量
57
期刊介绍: This online-only journal publishes original case reports on all types of cancer. In particular, we welcome not only case reports of educational value in the diagnosis and treatment of cancers, but also reports on molecularly analyzed cancer cases, including gene mutations, gene fusions, gene expression, and changes in copy number, regardless of their known clinical significance. Assessing the molecular analysis of a tumor usually requires a “cancer conference” in which experts from various fields discuss it. Even if the authors and their respective “cancer conference” were unable to determine the clinical significance of molecular changes at the time of submission and publication, their data may provide evidence that will help the scientific community develop precision medicine solutions in the future. We welcome case reports with reviews of the literature on similar cases, as they are more useful and valuable to readers than are reports of rare cases. International Cancer Conference Journal is the official publication of the Japan Society of Clinical Oncology (JSCO). - Presents an online-only collection of original case reports on all types of cancer - In particular, welcomes molecularly analyzed cancer cases - The Official Publication of the Japan Society of Clinical Oncology (JSCO)
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信